Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA) variations predict tumor response to systemic treatment (so-called molecular response) earlier than radiological assessment. However, a standardized categorization of molecular response is an unmet clinical need. Liquid biopsy-RECIST (LB-RECIST), based on aggregate variant allele frequency (aggVAF; sum of all detected variant allele frequencies in a sample) variations, has been proposed to stratify molecular response. Metastatic colorectal cancer (mCRC) may be an attractive clinical scenario for LB-RECIST clinical implementation; however, specific data on clinical validity is still lacking.

Patients and methods

The prospective PLATFORM-B study enrolled 130 mCRC patients who received standard frontline treatment and underwent serial ct

SUBMITTER: Martelli V 

PROVIDER: S-EPMC12446507 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature